Zacks Investment Research Lowers Cambrex Corporation (NYSE:CBM) to Hold
Zacks Investment Research downgraded shares of Cambrex Corporation (NYSE:CBM) from a buy rating to a hold rating in a research note released on Tuesday, July 4th.
According to Zacks, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems. “
Other equities research analysts also recently issued research reports about the company. BidaskClub upgraded Cambrex Corporation from a sell rating to a hold rating in a research report on Saturday, June 10th. ValuEngine downgraded Cambrex Corporation from a buy rating to a hold rating in a research report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $64.00.
Cambrex Corporation (CBM) traded down 5.34% during trading on Tuesday, reaching $58.50. The company’s stock had a trading volume of 1,285,934 shares. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The firm has a 50-day moving average price of $58.97 and a 200-day moving average price of $55.37. The firm has a market capitalization of $1.91 billion, a P/E ratio of 22.27 and a beta of 2.28.
Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting analysts’ consensus estimates of $0.76. Cambrex Corporation had a return on equity of 24.92% and a net margin of 17.36%. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. On average, equities analysts anticipate that Cambrex Corporation will post $3.02 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/04/cambrex-corporation-nysecbm-lowered-to-hold-at-zacks-investment-research-updated-updated-updated.html.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $54.19, for a total transaction of $650,280.00. Following the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,165,824.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Leon J. Hendrix, Jr. sold 20,656 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $55.95, for a total transaction of $1,155,703.20. Following the sale, the director now directly owns 74,662 shares in the company, valued at $4,177,338.90. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,656 shares of company stock worth $4,064,423. Company insiders own 2.48% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. State Street Corp increased its stake in shares of Cambrex Corporation by 5.3% in the fourth quarter. State Street Corp now owns 689,513 shares of the biotechnology company’s stock valued at $37,198,000 after buying an additional 34,532 shares during the period. Federated Investors Inc. PA increased its position in Cambrex Corporation by 31.0% in the fourth quarter. Federated Investors Inc. PA now owns 10,898 shares of the biotechnology company’s stock worth $588,000 after buying an additional 2,581 shares during the period. FMR LLC increased its position in Cambrex Corporation by 44.7% in the fourth quarter. FMR LLC now owns 504,448 shares of the biotechnology company’s stock worth $27,214,000 after buying an additional 155,753 shares during the period. Envestnet Asset Management Inc. increased its position in Cambrex Corporation by 152.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 9,966 shares of the biotechnology company’s stock worth $536,000 after buying an additional 6,022 shares during the period. Finally, Two Sigma Investments LP bought a new position in Cambrex Corporation during the fourth quarter worth $2,048,000. 98.28% of the stock is currently owned by institutional investors.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related stocks with our FREE daily email newsletter.